Related Experiment Video
Updated: Aug 23, 2025
04:15
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
1.9K
Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute
Nan Zhang1, Xiaoyan Liu1, Jinxian Wu1
1Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Therapeutic Advances in Hematology
|November 3, 2022
Summary
Intercellular adhesion molecule-2 (ICAM2) in serum can improve risk stratification for acute myeloid leukemia (AML) patients. This finding aids clinical decisions for intermediate-risk AML, enhancing treatment strategies.
Area of Science:
- Hematology
- Oncology
- Proteomics
Background:
- Clinical risk classification for acute myeloid leukemia (AML) relies on cytogenetic and molecular data.
- Optimal treatment for intermediate-risk AML remains uncertain, necessitating improved prognostic stratification.
Purpose of the Study:
- To identify serum protein biomarkers for refining risk stratification in AML patients.
- To enhance clinical decision-making for intermediate-risk AML.
Main Methods:
- Retrospective study utilizing label-free proteomics to analyze serum protein abundance.
- Integration of transcriptomic data to identify key altered markers.
- Survival analysis using Kaplan-Meier and multivariate Cox regression.
Main Results:
- Differential expression of serum proteins identified in AML patients.
- Intercellular adhesion molecule-2 (ICAM2) showed significant survival prediction value in intermediate-risk AML.
- ICAM2 expression improved risk stratification, distinguishing patient groups with comparable survival probabilities to established classifications.
Conclusions:
- Incorporating ICAM2 expression into AML risk classification refines intermediate-risk stratification.
- This provides valuable information for clinical decision-making in AML management.
